Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
Lupus Sci Med. 2025;12(1):e001517
Patient-reported outcomes from the deucravacitinib, 48-week, phase II, PAISLEY study show that patients with SLE experienced greater improvements in pain, fatigue and health-related quality-of-life scores at Week 48 with deucravacitinib versus placebo treatment.
Mosca, et al. describe improvements in PROs, including pain, fatigue and HRQoL, collected as exploratory endpoints in the PAISLEY study, supporting moving to phase III to further evaluate the effects of deucravacitinib in patients with active SLE.
